CORRECTION: Biosimilar Preferred Drug List (PDL) 2026 Update
Effective January 1, 2026, the Department will add preferred and non-preferred drugs to the Biosimilar PDL.
Preferred drugs added:
- Q 9996 Ustekinumab-ttwe SubQ
- Q 9997 Ustekinumab-ttwe I.V.
- Q5140 - adalimumab-fkjp
- Q5141 - YUFLYMA, adalimumab-aaty
- Q5142 - SIMLANDI, adalimumad-ryvk
- Q5143 - CYTEZLO, adalimumab-adbm
- Q5144 - IDACIO, adalimumab-aacf
- Q5145 - ABRILADA, adalimumab-afzb
Change from preferred to non-preferred drug: